5th August 2021 Pricing-Free The Decentralized Finance (“DeFi”) Industry offers a vast set of opportunities and has its set of challenges, with market finance volatility and risks increasing accordingly. The DeFi Conference 2021 is being held on 5th August 2021. This one-day free online event is a great learning and informative platform for businesses, academics, investors, and entrepreneurs to better understand the decentralized finance industry and explore the opportunities that this space offers. The DeFi Conference 2021 is organized by Bitcoin Events, a pioneer events company that hosts world-class bitcoin and blockchain conferences in Africa. The event will bring forth an unparalleled team of DeFi industry leaders and change-makers to share their experiences about how they are shaping the next era of global finance. Why should You attend the DeFi Conference 2021? 

• Connect and engage with 35+ World-Class Speakers and dynamic personas of the DeFi space as they speak about the disruptive products, services, and platforms of the DeFi Industry that they have built over the years, and the challenges surrounding these products.
• The event will showcase 2 tracks with one dedicated to DeFi and the other one to NFTs. These tracks will feature interesting topics on innovative DeFi ideas and the latest developments in the decentralized finance space.
• This conference offers a powerful medium to connect and learn from the reputed industry personnel across a spectrum of industries like insurance, finance, trading, investments, and so on.

This high-impact innovative event will feature two tracks, one about DeFi and the other about NFTs. Attendees can engage with influential DeFi industry leaders as they cover topics on financial inclusion, open finance, and the challenges in compliance, security, adoption, and regulation. New businesses and startups can gain insights from the experience of the industry veterans to develop strategies for their businesses and successful DeFi implementation. The DeFi Industry offers a huge palette of opportunities that industries, corporates, entrepreneurs, and capitalists can leverage. This conference is a viable learning platform for these sectors to gather in-depth financial information regarding the Decentralized finance industry and apply it to their business. Exhibitors will showcase their latest blockchain and cryptocurrency solutions and get a chance to interact with the attendees and establish healthy networking. In this event, like-minded individuals connect and learn about some of the most interesting blockchain use cases from a range of leading industries, international experts, startups in the Blockchain arena. For more information regarding the details of the event, please visit http://bitcoinevents.co.za/defi-conference-2021/.

• CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments
• Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway
• CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the last couple of months, demonstrating the company’s operational, financial, and strategic strengths and continuously de-risking its lead candidate Berubicin clinical program. According to a company press release providing critical operational updates, the company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (“GBM”). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021 (https://ibn.fm/57nx3). GBM is an aggressive type of brain cancer that is often difficult to treat. Most treatments only slow the progression of cancer and reduce the symptoms. Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. The designation will enable more frequent interactions between the FDA and the company, expediting the development and review process for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer (https://ibn.fm/ObyTP). “Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,” he explained. In addition to the success of Fast Track designation and commencing enrollment in the clinical trial, CNS Pharmaceuticals has secured an additional $4.7 million in gross proceeds from the Company’s ATM facility at an average price of $2.32. These proceeds help fund the ongoing clinical programs and have extended the company’s cash runway to Q2 2022. These developments are the latest of multiple achievements the company has reported since its original IPO in November 2019. These achievements include:

• Obtaining orphan drug designation for Berubicin
• Receiving approval of the Investigational New Drug (“IND”) application
• Designing a clinical trial that may support an accelerated pathway to registration
• Manufacturing a clinical supply of Berubicin in both the U.S. and Europe under a dual-track strategy that addressed COVID-related restrictions on imports

“In a mere 18 months from our IPO, our laser focus on this program created a potentially pivotal study now open for enrollment, with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devastating and heretofore incurable disease,” Climaco added. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• The new version of the Fan Pass platform (v2.0) for mobile and desktop is scheduled for release one year after its debut, with new and improved offerings outlined in a new corporate presentation
• Artists and fans both benefit from the updated version, gaining an easy-to-use dashboard that tracks ticket and merchandise sales (for artists) and special access into the lives of the artists (for fans)
• Friendable estimates that if three celebrity partners with 10 million followers each marketed the Fan Pass platform and 1% of those followers subscribed, that would bring 300,000 new subscribers to the artist streaming platform
• A subscription to the Fan Pass platform is $2.99 all-access, and additional PPV events are priced individually on a case-by-case basis

With the first anniversary of Friendable’s (OTC: FDBL)  flagship offering, the Fan Pass platform, drawing near, the company reports a key milestone – 5,000 new sign-ups for the artist streaming platform. The Fan Pass platform was created to give fans exclusive access to the lives of their favorite artists, and artists a virtual stage to earn revenue, engage fans, and above all else, perform. “New artist sign-ups on Fan Pass continue to rise, and as we near completion of our new website and all digital media assets, we expect to also see a significant increase in brand awareness, app downloads, artist sign-ups, and a swarm of fans that will use our app and begin to drive revenue increases for their favorite artists, as well as our business,” commented Robert A. Rositano, Jr., CEO and co-founder of Friendable (https://nnw.fm/lQG3z). (https://ibn.fm/NsSAo). The new milestone in artist sign-ups was announced just days before the Fan Pass platform’s version 2.0 for mobile and web is set to release. The updated version rolls out on July 24, which also marks the artist streaming platform’s one-year anniversary. Along with the new version come many new offerings for both artists and fans, which were laid out in the company’s new corporate presentation. Artists on the streaming platform will gain access to features such as:

• Sound checks to test equipment before going live
• Integrated dashboard – includes comprehensive analytics, tutorials on how to go live, chat support, etc.)
• Mobile streaming capabilities
• Instant artist access
• Live viewer count
• The ability to receive donations/tips from fans directly
• Subscription packages
• Instant dashboard updates (ticket and merchandise sales)
• Custom designed merchandise

Fans using the streaming platform will gain:

• An exclusive look into the everyday lives of favorite musical artists
• Backstage access before, during, and after an event
• Special interviews and one-on-one videos
• Behind-the-scenes view on music videos, films, or photo-shoot sets and green rooms
• Access to custom merchandise

The artist streaming platform is a subscription-based service for fans, costing $2.99 per month all-access. Fans can also purchase tickets to pay-per-view events, priced on a case-by-case basis. Artists will be able to see the revenue they are earning right on the new and improved artist dashboard to be released with version 2.0. “Our metrics show great potential for scale and v2.0 of Fan Pass is designed to provide and allow a solid, scalable infrastructure that is ready to handle the demand we have identified since launch,” Rositano added. “We will continue to keep shareholders up-to-date as we progress along this exciting path of growth.” The revenue brought in by the Fan Pass platform is generated by growing the subscriber base, and offering paid access to streaming events. The company’s presentation points out that if celebrity partners leverage their social following market to Fan Pass, the exposure could be exponential. Three celebrities with 10 million followers provide a social reach of 30 million followers (potentially) for the artist streaming platform. Even if one percent (1%) of these followers were to subscribe, the Fan Pass platform would be looking at 300,000 subscribers, according to Friendable. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://nnw.fm/FDBL http://ibn.fm/FDBL

• New numbers project that cannabis beverage market will reach $2.8 billion by 2025
• Increasing demand for the health and wellness drinks is contributing to market growth
• BevCanna’s scalable, flexible manufacturing process provides white label solutions for third-party companies

A new report that forecasts the cannabis beverage market will grow at 17.85% CAGR by 2025 has companies such as BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) anticipating increased numbers as well (https://ibn.fm/zh9Pa). A leader in the space, BevCanna is looking to leverage its position in the growing market as a white label manufacturer of infused-cannabis beverage brands. According to a recent Million Insights study, the global cannabis beverages market is estimated to reach $2.8 billion by 2025 and is projected to grow at a CAGR of 17.8% from 2019 to 2025. “The increasing demand for the health and wellness drink is boosting the market growth,” the report states. “Additionally, the increasing acceptance of cannabis for medical purposes in various countries is expected to increase the production of cannabis beverages.” The report pointed to cannabis drinks to “help treat cancer, pain and neurological disorders. Further, the increasing interest of consumers for cannabis edible is expected to indirectly drive the cannabis beverage market growth. Consumers are shifting from smoking cannabis to tinctures, chocolates, edibles and other beverages,” the report states. “All these key factors are anticipated to foster the demand for the product in the next few years.” Another insight offered by the report is the rising demand for cannabis drinks from cafes, restaurants, lounges and club as “the changing consumer preference and decline in the sale of alcoholic drinks is increasing beverage consumption.” All these factors combine to fuel the anticipated growth in the expanding cannabis beverage market. Because BevCanna is a diversified health and wellness beverage and natural products company, the company is particularly well qualified to meet the demand for these types of drinks. In addition, the BevCanna team boasts decades of experience creating, branding and distributing wellness and recreational beverages that resonate with consumers on a global scale. Utilizing this unique expertise, BevCanna manufactures its own product lines: Pure Therapy and TRACE. Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (“CBD”) products, throughout North America. BevCanna’s TRACE product line features unique and ancient minerals that offer a broad range of wellness properties including immune function, cognitive performance, and gut health. In addition, the company’s scalable and flexible manufacturing process provides white label solutions for third-party companies looking to enter this promising space with the highest-quality products available. A manufacturer of traditional and cannabis-infused beverage brands, the company is serving a growing roster of white-label clients. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• GTVH has new office space to develop, manage, market all company ventures
• Lavish Entertainment’s goal is to “throw the most epic raves in the world”
• Founder notes spinoff of two companies slated to happen after GTVH completes audited financials

Golden Triangle Ventures (OTC: GTVH) has announced key milestones reached by its entertainment division, which owns Lavish Entertainment Inc. and is doing business as EpicRaves. GTVH president Steffan Dalsgaard provided a summary of the division’s impressive progress in a mid-year letter to shareholders (https://ibn.fm/bikQI). In the letter, Dalsgaard noted significant progress made by the company’s entertainment division, including moving into new office space in Las Vegas and building “a place where we could not only develop, manage, and market all the companies within Golden Triangle Ventures but also have a home for all our in-house concert production equipment so we could organize livestreamed events and highlight the great artists that sign on to our Syndicate Bass Records label.” The letter noted that owning the production, acquiring professional equipment and learning how to operate that equipment were bringing the company closer to its final goal. “Our vision is to throw the most epic raves in the world, and I am so confident that we are going to create events that leave our guests with a true experience unlike anything this city has seen,” said Dalsgaard. “Our very first show back is held on July 23, 2021, at Hard Rock Live in Las Vegas, and we will be highlighting some of the artists that we expect to sign as the first release within our label. This record label is a bit different than most because we will not only be highlighting some very talented musical artists that make experimental and unique bass music, but we will also be highlighting amazing visual artists that will create custom video content on each release we drop.” In addition, Dalsgaard mentioned the company’s focus on building a platform that can monetize and share its events to the world through virtual reality or directly on TV. “This platform is currently being developed by some of the best in the business, and we now have a go-to market strategy that will grow into a platform unlike anything in the world,” Dalsgaard noted. “The first phase is near complete, and we will soon be getting a demonstration of the platform in person.” Dalsgaard also reported that the company’s plan to purchase the Sahara Event Center was, while not guaranteed, at least moving forward. Dalsgaard also alluded to two major projects that he called “the biggest opportunities I have ever worked towards. We are working on patenting both projects globally, and we plan to share full details on them immediately after.” Finally, Dalsgaard provided an update regarding the company’s earlier announcement that Lavish Entertainment and Global Health Services would spin off of Golden Triangle Ventures into their own trading entities and that all the shareholders who owned GTVH by February 19, 2021, would receive a 1:1 dividend in these new entities. The move is slated to happen after Golden Triangle completes its audited financials. “We have retained Malone & Bailey to do full audited financials on our company,” stated Dalsgaard, “and we will move forward to complete this goal once all these acquisitions are in place and the world understands our ultimate vision. Once Global Health Services and Lavish Entertainment spin off, Golden Triangle Ventures will own about 25% of each company in equity, so all our GTVH shareholders indirectly own a piece of both companies, regardless of if you owned our stock prior to the declared dividend date.” Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint-venture with established entities that management can assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• Former head of psychiatry products at FDA joins Cybin team.
• Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory pathway as it studies and develops psychedelic medicines, says Alex Belser, Cybin’s chief clinical officer. “Psychedelic medicines don’t fit neatly into the old models for how drugs are studied, reviewed and approved,” says Belser. “We brought together experts to help us work within existing clinical and regulatory frameworks while realizing that psychedelics require innovative methods and a new approach.” During his tenure at the FDA, Laughren supervised the research and review of all new psychiatric drug applications and development projects in clinical testing. In addition, he assisted in the design and interpretation of clinical trials for psychiatric drugs. Laughren left the FDA in 2021 to start his own consulting company and has spent the last decade helping psychiatric pharmaceutical drug makers gain FDA approval for new drugs. Cybin CEO Doug Drysdale notes that Laughren’s FDA experience is invaluable as the company moves into the “next chapter” with studies on psilocybin, the psychedelic compound found in “magic” mushrooms. “Building and maintaining strong relationships and communications channels with regulators will be important for Cybin as their understanding of psychedelic therapeutics evolves over time,” says Drysdale. Although Cybin is currently conducting studies on psilocybin, the company is also developing novel molecules based on other psychedelic compounds. In fact, the company has 13 provisional patent applications filed for novel psychedelic molecules. Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• AmpliTech Group, a designer and developer of technology that enhances radio frequency (“RF”) transmissions for satellites, 5G, IoT and other applications recently reported record order bookings and orders in progress under deadline
• Thaw in COVID pandemic’s business impact is very encouraging for future business opportunities
• Products serve satellite communications, space, telecommunications (5G/6G) and military defense markets
• Recapitalized and listed on Nasdaq to support variety of growth opportunities
• Cash position of approximately $30M – with no debt

Radio Frequency component designer and manufacturer AmpliTech Group (NASDAQ: AMPG) recently reported record bookings and a record backlog (defined as contractually obligated purchase orders with a deadline for delivery) of $2.4M in conjunction with Q1 results. The New York-based company has delivered industry standard quality products for leaders in satellite communications, space, telecommunications (5G/6G) and military defense markets for nearly 20 years. The company netted ~$30M in cash and began trading on the Nasdaq capital market earlier this year. CEO & CTO Fawad Maqbool expects growing business activity and customer demand from mass reopening of its market segments with steady decline in COVID-19 pandemic impact on customer activity and ramping of company’s business development efforts. “We expect the reopening to benefit AmpliTech going forward, along with potential pent-up demand for solutions in 5G, satellite, cyber security, quantum computing and other markets that have developed over the past year,” Maqbool stated in the Q1 release (https://ibn.fm/dpLQw). “To support the substantial opportunities we have identified, we completed a recapitalization of our company over the first four months of 2021, providing over $30M in current funding to support our growth and demonstrate financial strength to our customers and partners. Additionally, we also up-listed our common stock to Nasdaq to position our company for greater visibility, liquidity and access to a much broader pool of potential investors.” AmpliTech’s Q1 release reports that it achieved design wins reflecting its low noise amplifier (“LNA”) products’ performance, durability, and heat dissipation. It also established a premier on-site testing laboratory enabling it to test its products under extreme temperatures and other conditions to ensure product quality and reduce variable testing costs. Additionally, to address ever increasing security concerns in the communications space, AmpliTech has begun development of an enhanced solution incorporating hardware encryption into its signal amplifiers. These efforts aim to provide secure hardware chip-based encryption to secure 5G network transfer without negatively impacting data speeds and to support increasing IoT (Internet of Things) device adoption. While the LNA products provide significant value and return on investment for satellite network applications in space, AmpliTech sees other exciting applications. Recently, AmpliTech received a developmental order for a special cryogenic-cooled probe head used to facilitate studies on materials, molecules and drugs to treat diseases (https://ibn.fm/6JcA0). The company is well-positioned to expand its market reach given the industry leading quality and performance of its amplifiers. AmpliTech believes the market need for its solutions should grow as the demand for higher fidelity wireless communication systems increases at an exponential rate. The overall market for RF components was valued at $23.79 billion last year and is expected to grow at a compound annual growth rate of 14% through 2025, according to market analysts at Grand View Research (https://ibn.fm/tjvXK). For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Science continues to substantiate use of cannabis for pain relief, epileptic seizure control
• Research suggests strains with optimized cannabinoid profiles are more effective
• PACR produces premium top-quality strains cultivated using genetics-first approach to optimize cannabinoid profiles
• Genetic cultivation techniques allow selection for specific growing environments, maximum yields

With a growing list of use cases spanning pain relief to seizure control, the medicinal use of cannabis goes back thousands of years (https://ibn.fm/X68wD). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company, leverages a genetics-focused approach to producing premium-quality strains with optimum cannabinoid profiles that are prized among consumers, including those in the hyper-growth medicinal space. Recent studies suggest that tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), along with hundreds of other potentially active compounds, can help relieve pain and control seizures. Referred to as “full-spectrum” cannabis, these specialized strains with optimized profiles were shown to be more effective due to the synergistic effect between specific cannabinoids and terpenes, organic compounds that enhance the effect of cannabis. Pac Roots leverages high-end genetics and specialized cultivars to produce distinctive cannabis products, specifically strains that can be tailored for medicinal purposes. This is made possible through Pac Roots’ exclusive partnership with Phenome One, a plant breeding management and analytics firm that gives the Company access to one of the largest live genetic libraries in Canada. Through Phenome One’s platform, Pac Roots has access to a massive database detailing over 350 unique laboratory-analyzed and rigorously field-tested cannabis cultivars that support each stage of the breeding process. Supported by data going back over 30 years, Pac Roots is also able to produce top-quality anti-fungal strains that are bred to thrive in specific climates – including the Fraser Valley in British Columbia where the Company recently made a sizeable land purchase. With its high-quality soil and favorable climate, the Fraser Valley Regional District is known worldwide as one of Canada’s most productive and intensively farmed areas. Pac Roots recently made the strategic purchase through a share purchase agreement that gave the Company outright ownership of 250 acres of land spread over nine parcels. “The addition of such a substantial package of land to our portfolio is a major step for PacRoots. We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre,” said Pac Roots President and CEO Patrick Elliott (https://ibn.fm/0cuZr). “This land has no zoning restrictions and is not situated within the Agricultural Land Reserve, which provides for infinite development possibilities.” Medicinal cannabis products are growing in popularity across all demographics because of increased consumer awareness and the growing body of scientific evidence. As consumer demand for medicinal cannabis increases, the ability to deliver top-quality strains with optimized cannabinoid profiles is growing in importance. Pac Roots’ novel genetics-based approach to producing premium-grade cannabis, along with its portfolio of pristine land and production assets, is positioning the company favorably as a leader in the rapidly growing industry. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• The Mobius Interactive flagship brand, Mobius.bet, is a top sponsor for the next six matches of the 2021 FIFA World Cup Soccer Qualifiers in Brazil
• The Mobius.bet brand will be showcased on Globo TV Brazil, attracting 35 – 40 million viewers per match
• By partnering with Globo TV, Mobius Interactive will reach more sports enthusiasts, showcasing the Mobius.bet brand and growing its market reach

Mobius Interactive has signed a lucrative sponsorship agreement to display its flagship brand, Mobius.bet, on national TV in Brazil for the 2021 FIFA World Cup Qualifiers, marking the company’s entry into the expanding Brazilian iGaming industry. Mobius Interactive has burst onto the scene of this booming market with its main brand, Mobius.bet – based upon research and knowledge of the region.This strategic move will capitalize on the current surge in Latin America’s iGaming and Esports markets. This iGaming industry is projected to grow at a CAGR of 11.4% between 2018 and 2023, ultimately posting total revenues of $6.29 billion. This venture into the Brazilian market is well-calculated and perfectly-timed. Mobius Interactive is pulling out all the stops in Brazil, getting in early to capitalize on this situational opportunity with tremendous growth potential. The agreement to display Mobius.bet ads on Brazilian national TV opens a new front in Mobius Interactive’s campaign to conquer the lucrative Latin American gaming market. With Globo TV, Brazil’s largest television station, Mobius Interactive is able to reach 99.5% of the country’s population of 211 million. Mobius Interactive’s partnership with Globo TV presents the ideal opportunity take full advantage of this market—a market set for exponential growth. It is estimated that the Brazil World Cup qualifiers will attract about 35 million viewers per match on Globo TV. The highly-anticipated game between Brazil and its archrival, Argentina, is projected to attract about 40 million viewers. Mobius Interactive is capitalizing on these impressive numbers to push its brand in the Latin American market, taking full advantage of this vast audience and the football culture of Brazil, a soccer powerhouse with more World Cup victories than any other team in history. The matches:

• Chile vs Brazil (2nd September)
• Brazil vs Peru (7th September)
• Venezuela vs Brazil (7th October)
• Brazil vs Uruguay (12th October)
• Brazil vs Colombia (11th November)
• Argentina vs Brazil (16th November)

Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685  gary@mobiusinteractive.ltd Seamus Byrne – VP Corporate Development 1 (902) 441-5757  seamus.byrne@halifaxcitrus.ca Tracey Miller – VP Mergers & Acquisitions 1 (604) 355-5589  tracey@mobiusinteractive.ltd  For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• XPhyto partners with AGORA t to grow its brand and overall market share
• The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
• AGORA is known for its online marketing, conferences, broadcasting and investor relations services
• Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020. The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of XPhyto, equivalent to 0.03% of the issued and outstanding common shares (https://ibn.fm/GVoHm). AGORA is known for its online marketing, conferences, broadcasting and investor relations services for the global market. With its online community, AGORA is able to help investors and small companies to not only discuss but also discover small cap stocks and investment opportunities (https://ibn.fm/BgDHx). Its client list is constantly growing and is currently made up of companies such CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others (https://ibn.fm/cuUyv). XPhyto plans on capitalizing on the experience that AGORA has by working with the other clients and leveraging on this to grow its brand and overall market share. XPhyto is a life sciences technology accelerator, focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its biggest achievement so far has been its rapid COVID-19 PCR test kit that reduces test turnaround times to less than 30 minutes (https://ibn.fm/KELop). The company has operations in Europe and North America, with an operational focus in Germany. This partnership with AGORA has the potential to push the XPhyto brand even further, allowing it to appeal to more customers and fulfil its agenda for growth and commercialization for the European market. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF